We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 30, 2021

Multiple Doses of Cagrilintide With Semaglutide 2.4 mg for Weight Management

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Concomitant Administration of Multiple Doses of Cagrilintide With Semaglutide 2·4 mg for Weight Management: A Randomised, Controlled, Phase 1b Trial
Lancet 2021 Apr 22;[EPub Ahead of Print], LB Enebo, KK Berthelsen, M Kankam, MT Lund, DM Rubino, A Satylganova, DCW Lau

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading